Toggle menu

Michelle Coakley

Senior Research Nurse - Stroke/Neurosurgery

Research Interests:
Stroke, Neurosurgery
Qualifications:
BSc in Nursing (Intellectual Disability) (Hons), BSc in Nursing (Adult), Principles & Practice of Neuroscience Nursing (Level 9 module), MSc Advancing Nursing Practice
Michelle Coakley

Michelle is trained in both Learning Disability and Adult Nursing. Her broad range of nursing experience includes working with adults and children with learning disabilities, acquired head injuries and additional support needs, adults recovering from neurosurgery and children with complex healthcare needs including long-term ventilation.

 

Michelle recruits to and co-ordinates a variety of stroke and neurosurgery trials, including acute treatment, secondary stroke prevention, observational studies and randomized controlled trials. Notably, she is currently co-ordinating a commercial phase 2 randomized controlled drug trial.

 

Michelle played a role in recruiting to many COVID -19 trials and assisted in the co-ordination of the COVID-19 vaccine trial. She also managed to complete her MSc in Advancing Nursing Practice during this time. Michelle also holds an honorary clinical fellowship with the University of Edinburgh.


Trials

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.

The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.  

This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.

Participants will be asked to return for 6 visits across 12 months to evaluate their health.

Across the UK the trial aims to recruit 10,260 volunteers.

If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh

Read more

COV_002 Vaccine Trial

The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)

ETNA

ETNA: Edinburgh Transient and Neurological attack: A Cohort Study

Patients frequently present with minor neurological symptoms where a diagnosis of transient ischaemic attack (TIA) or minor stroke is difficult to make positively or to exclude reasonably. For these patients, clinicians are uncertain whether they should: (a) reassure most patients that their symptoms are benign; (b) treat most patients with antiplatelet or other vascular prevention; or (c) stratify stroke risk further using clinical features or brain imaging.
This is important because clinical diagnosis is difficult. Mis-diagnosis is not infrequent and leads to harm from preventable recurrent stroke and costs to health systems from extra care and legal liabilities.
All ETNA participants will receive an MRI scan and the study aims to establish the feasibility and methods for a larger study of diagnostic utility of MR brain imaging and estimate the effects of MRI on clinician decision making.
This study has been recruiting in the Emergency Dept, inpatient wards and TIA clinics since August 2018. We aim to recruit 270 participants and have almost reached our target!

Read more

ETNA

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

BRAINED Study

Molecular and cellular analysis of intracranial tumours

Read more

BRAINED Study

Molecular and cellular analysis of intracranial tumours

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)